Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease.

Creator(s)

Kyle Gress
Julie A. Bass, Children's Mercy HospitalFollow
Ryan S Funk
Ryan Morrow, Children's Mercy HospitalFollow
Rachel Hasenkamp, Children's Mercy HospitalFollow
Valentina Shakhnovich, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

6-9-2020

Identifier

DOI: 10.3389/fimmu.2020.01148; PMCID: PMC7295975

Journal Title

Front Immunol

Volume

11

Keywords

TNF-α; adalimumab; anti-drug antibodies; biologics; children; immunogenicity; inflammatory bowel disease; infliximab

Comments

Grant support

• KL2 TR002367/TR/NCATS NIH HHS/United States
• L40 TR000598/TR/NCATS NIH HHS/United States
• P20 GM130423/GM/NIGMS NIH HHS/United States

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Publisher's Link: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01148/full

Recommended Citation

Gress K, Bass JA, Funk RS, Morrow RP, Hasenkamp R, Shakhnovich V. Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease. Front Immunol. 2020;11:1148. Published 2020 Jun 9. doi:10.3389/fimmu.2020.01148